Related Experiment Video
Updated: Jun 22, 2025
10:30
Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
Published on: January 25, 2017
8.8K
Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease
Arno R Bourgonje1, Ryan C Ungaro2, Saurabh Mehandru1
1The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Gastroenterology
|June 30, 2024
Summary
Interleukin 23 (IL-23) inhibitors targeting the p19 subunit show promise for treating inflammatory bowel diseases (IBDs). This review details their mechanisms, efficacy, and safety, guiding precision medicine approaches.
Area of Science:
- Immunology
- Gastroenterology
Background:
- Interleukin 23 (IL-23) is crucial for intestinal homeostasis but also drives inflammatory bowel diseases (IBDs).
- IL-23 is a heterodimer comprising p19 and p40 subunits.
- Targeting the IL-23 p19 subunit with monoclonal antibodies is a developing therapeutic strategy for IBDs.
Purpose of the Study:
- To review the pharmacodynamics, pharmacokinetics, and therapeutic mechanisms of IL-23p19 inhibitors.
- To evaluate the efficacy, safety, and tolerability of these inhibitors in IBD and other immune-mediated inflammatory diseases.
- To explore combination therapies and future directions for precision medicine in IBD treatment.
Main Methods:
- Literature review of preclinical and clinical studies on IL-23p19 inhibitors.
- Analysis of data on drug properties, mechanism of action, and clinical outcomes.
- Evaluation of safety profiles and potential for combination therapies.
Main Results:
- IL-23p19 inhibitors demonstrate specific targeting of the IL-23 pathway.
- Clinical data indicate favorable efficacy, safety, and tolerability profiles in IBD treatment.
- Studies in other inflammatory diseases provide further insights into their therapeutic potential.
Conclusions:
- IL-23p19 inhibitors represent a significant advancement in IBD management.
- Understanding their precise mechanisms and clinical data supports their role in precision medicine.
- Future research should focus on optimizing their use, potentially in combination therapies, for improved patient outcomes.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
01:29Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
01:24T Cell Types and Functions
998
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
998
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
01:29Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115